Chemomab Therapeutics (CMMB) Non-Current Assets (2017 - 2025)
Chemomab Therapeutics (CMMB) posted Non-Current Assets of $387000.0 for Q4 2025, down 12.44% on a QoQ basis from $442000.0 in Q3 2025, and down 58.12% year-over-year from $924000.0 in Q4 2024.
Chemomab Therapeutics (CMMB) Non-Current Assets (2017 - 2025) Analysis & Trends
Chemomab Therapeutics' Non-Current Assets history runs 9 years deep, the most recent figure standing at $387000.0 for Q4 2025.
- Quarterly Non-Current Assets fell 58.12% year-over-year to $387000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $387000.0 (down 58.12% YoY) and the FY2025 annual result came in at $387000.0, down 58.12% from the prior year.
- Non-Current Assets was $387000.0 for Q4 2025 at Chemomab Therapeutics, down from $442000.0 in the prior quarter.
- Across five years, Non-Current Assets topped out at $1.7 million in Q2 2021 and bottomed at $387000.0 in Q4 2025.
- A 5-year average of $1.1 million and a median of $1.2 million in 2023 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2021 — Non-Current Assets surged 430.9% — and 2025, when it plunged 58.12%.
- Chemomab Therapeutics' Non-Current Assets stood at $1.7 million in 2021, then retreated by 20.3% to $1.3 million in 2022, then retreated by 5.5% to $1.3 million in 2023, then retreated by 26.32% to $924000.0 in 2024, then plunged by 58.12% to $387000.0 in 2025.
- Business Quant data shows CMMB's Non-Current Assets at $387000.0 in Q4 2025, $442000.0 in Q3 2025, and $515000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 21.65 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 5.83 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.95 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 3.95 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 14.75 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 22.66 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 289.41 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.96 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 285.82 Mn |
| 10 | Chemomab Therapeutics | 124.14 Mn | 113.77 Mn | - | 387,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 387,000.00 |
| Sep 30, 2025 | 442,000.00 |
| Jun 30, 2025 | 515,000.00 |
| Mar 31, 2025 | 842,000.00 |
| Dec 31, 2024 | 924,000.00 |
| Sep 30, 2024 | 1.01 Mn |
| Jun 30, 2024 | 1.09 Mn |
| Mar 31, 2024 | 1.17 Mn |
| Dec 31, 2023 | 1.25 Mn |
| Sep 30, 2023 | 1.05 Mn |
| Jun 30, 2023 | 1.14 Mn |
| Mar 31, 2023 | 1.24 Mn |
| Dec 31, 2022 | 1.33 Mn |
| Sep 30, 2022 | 1.49 Mn |
| Jun 30, 2022 | 1.55 Mn |
| Mar 31, 2022 | 1.62 Mn |
| Dec 31, 2021 | 1.67 Mn |
| Sep 30, 2021 | 1.60 Mn |
| Jun 30, 2021 | 1.68 Mn |
| Mar 31, 2021 | 600,000.00 |